1. Home
  2. NGNE vs LOCO Comparison

NGNE vs LOCO Comparison

Compare NGNE & LOCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$38.20

Market Cap

498.2M

Sector

Health Care

ML Signal

HOLD

Logo El Pollo Loco Holdings Inc.

LOCO

El Pollo Loco Holdings Inc.

HOLD

Current Price

$16.73

Market Cap

411.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
LOCO
Founded
2003
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
498.2M
411.3M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
NGNE
LOCO
Price
$38.20
$16.73
Analyst Decision
Strong Buy
Buy
Analyst Count
7
4
Target Price
$63.57
$14.17
AVG Volume (30 Days)
307.2K
301.5K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
0.93
4.65
EPS
N/A
0.27
Revenue
N/A
$401,701,000.00
Revenue This Year
N/A
$3.60
Revenue Next Year
N/A
$3.98
P/E Ratio
N/A
$61.67
Revenue Growth
N/A
5.68
52 Week Low
$15.93
$8.99
52 Week High
$43.66
$17.40

Technical Indicators

Market Signals
Indicator
NGNE
LOCO
Relative Strength Index (RSI) 62.20 63.11
Support Level $18.24 $13.52
Resistance Level N/A $17.40
Average True Range (ATR) 3.05 0.49
MACD 0.74 -0.05
Stochastic Oscillator 63.00 68.69

Price Performance

Historical Comparison
NGNE
LOCO

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About LOCO El Pollo Loco Holdings Inc.

El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. It specializes in fire-grilling citrus-marinated chicken and operates in the limited service restaurant market segment. Its offerings include Mexican-inspired menu items, including burritos, tostadas, bowls, salads, and bone-in chicken meals in various portion sizes. It also offers citrus-marinated fire-grilled chicken, along with a range of salsas and dressings that allow customers to customize their meals. The company operates in one operating segment. The majority of the company's revenue is derived from company-operated restaurant revenue.

Share on Social Networks: